Banking

Xenon’s Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency

<img class="img-responsive" src="https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2022/06/23/aapharma_0.png"><ul>
<li>Xenon Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://markets.businessinsider.com/stocks/xene-stock">XENE</a>) announced&nbsp;new efficacy data&nbsp;supporting the Phase 3 development of XEN1101.

Share this news on your Fb,Twitter and Whatsapp

File source

Times News Network:Latest News Headlines
Times News Network||Health||

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
Close